Takeda Pharmaceutical (TAK) Non-Current Deferred Tax Liability (2017 - 2026)

Takeda Pharmaceutical's Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $169.6 million for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability fell 26.76% year-over-year to $169.6 million; the TTM figure through Jun 2026 stood at $169.6 million (down 26.76% YoY), while the FY2026 annual figure was $178.1 million, down 22.84% from the prior year.
• Non-Current Deferred Tax Liability for Q2 2026 stood at $169.6 million, down from $170.9 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $3.9 billion in Q1 2022, with the low at $169.6 million in Q2 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $562.2 million (2024), against an average of $1.3 billion.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability plunged 81.87% in 2024, then declined 17.97% in 2025.
• Takeda Pharmaceutical's Non-Current Deferred Tax Liability stood at $2.8 billion in 2022, then sank by 67.29% to $900.0 million in 2023, then plunged by 72.47% to $247.8 million in 2024, then fell by 17.97% to $203.3 million in 2025, then fell by 16.54% to $169.6 million in 2026.
• Business Quant data shows TAK's Non-Current Deferred Tax Liability at $169.6 million in Q2 2026, $170.9 million in Q1 2026, and $203.3 million in Q4 2025.